Clinical trials: Psychotic Disorder
Schizophrenia
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
This study evaluated how well SEP-363856 works and how safe it is in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.
- Trial name
- NCT05628103
- Testing
- SEP-363856
- Where
- 25 sites in United States
- Volunteers
- 101 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone
Having a diagnosis of schizophrenia or bipolar disorder and being treated with certain of the newer antipsychotics are risk factors for development of diabetes.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00538642
- Testing
- ziprasidone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia, Schizoaffective Disorder
Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life
Purpose: To develop and test the feasibility of an exercise intervention that combines group walking, activity tracking, and heart rate monitoring, and determine the effectiveness of this intervention on the physical and mental…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorder
- Trial name
- PACE-life (NCT03757988)
- Testing
- Exercise Intervention- PACE-Life
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Psychosis
Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)
This study evaluates the safety and tolerability of Asenapine in elderly patients with psychosis.
- Trial name
- NCT00281320
- Testing
- Asenapine
- Volunteers
- 122 people
- Sponsor
- Organon and Co
Bipolar Disorder, Schizophrenia
Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders
Persons with serious mental illness (SMI) are at increased risk of cardiovascular disease (CVD). The goals of this study are to test a treatment, Life Goals Collaborative Care to help promote health behavior change and improve…
- Conditions
- Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder
- Trial name
- NCT01487668
- Testing
- Life Goals Collaborative Care
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
This Phase IV, randomized, parallel-group study is designed to evaluate the cataractogenic potential of quetiapine fumarate (SEROQUEL) compared with that of a putative non-cataractogenic antipsychotic medication risperidone…
- Trial name
- NCT00206102
- Testing
- quetiapine fumarate, risperidone
- Where
- 63 sites in United States
- Volunteers
- 1,098 people
- Sponsor
- AstraZeneca
Schizophrenia and Disorders With Psychotic Features
Specialized Treatment Early in Psychosis (STEP)
The purpose of this study is to understand the effectiveness of a specialized package of phase-specific treatments for individuals in the midst of their first episode of psychosis.
- Trial name
- STEP (NCT00309452)
- Testing
- Cognitive Behavioral Group Therapy, Cognitive remediation, Medications
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Yale University
Smoking Cessation, Cigarette Smoking
Treating Smokers With Mental Illness
This is a smoking cessation study that will enroll smokers who have been diagnosed with a severe mental illness. The study will use a combination of intensive tobacco treatment counseling and nicotine replacement therapy to…
- Conditions
- Smoking Cessation, Cigarette Smoking, Schizophrenia, Psychotic Disorders
- Trial name
- NCT03822416
- Testing
- Nicotine patch, Nicotine lozenge, Therapy
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Schizophrenia, Undifferentiated Type
Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients
After an initial screening visit, including an assessment of psychiatric disorders, patients stabilized on antipsychotic medication (aripiprazole or risperidone) for at least 6 weeks and control subjects will undergo an…
- Trial name
- NCT01109147
- Testing
- Imagery, pharmacogenetic sampling
- Where
- 2 sites in France
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Qualissima
Alcoholism, Schizophrenia
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
This placebo-controlled study is designed to evaluate the efficacy of glycine, an agonist of the glycine-B co-agonist site of the NMDA receptor, on alcohol consumption and craving as well as negative symptoms in schizophrenia.
- Trial name
- NCT00338598
- Testing
- Glycine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Akathisia, Drug-Induced, Dyskinesia, Drug-Induced
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
This study was designed to determine if preladenant (SCH 420814, MK-3814) can reduce drug-induced involuntary movements in participants with schizophrenia or schizoaffective disorder.
- Conditions
- Akathisia, Drug-Induced, Dyskinesia, Drug-Induced, Parkinsonian Disorders
- Trial name
- NCT00686699
- Testing
- Preladenant
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700
The purpose of this PET study is to verify the binding of Lu AF35700 after multiple oral dosing at the dopamine and the serotonin receptors in male patients with schizophrenia.
- Trial name
- NCT02333487
- Testing
- Lu AF35700
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
TMS Enhancement of Visual Plasticity in Schizophrenia
The major goal is to determine if Transcranial magnetic stimulation (TMS) enhances visual plasticity in schizophrenia. TMS sessions (sham/placebo and real TMS) will be conducted before two MRI scans with two weeks in-between to…
- Trial name
- NCT03220438
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia and Related Disorders
An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study
This is an open-label extension study to continue to evaluate the safety, tolerability and efficacy of the Repetitive Transcranial Magnetic Stimulation (rTMS) in subjects with schizophrenia or schizoaffective disorder who…
- Trial name
- NCT05526833
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Schizophrenia
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
To evaluate the overall effectiveness of aripiprazole intramuscular (IM) depot as maintenance treatment in patients with schizophrenia.
- Trial name
- ASPIRE (NCT00731549)
- Testing
- Aripiprazole IM Depot
- Where
- 214 sites in United States, Argentina and 26 more
- Volunteers
- 1,081 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients
This study will compare employment support with behavioral skills training to employment support alone in schizophrenia patients taking either risperidone or olanzapine to determine which is more effective in helping the patients…
- Trial name
- NCT00183625
- Testing
- Individual Placement and Support (Supported Employment), Social Skills Training, Olanzapine
- Where
- 2 sites in United States
- Volunteers
- 107 people
- Sponsor
- University of California, Los Angeles
Schizophrenia, Impulsive Behavior
Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia
The purpose of this study is to test whether nicotine, a drug that activates receptors called nicotinic acetylcholine receptors in the brain, improves the ability to make or withhold responses to faces that are either emotionally…
- Trial name
- NCT03838484
- Testing
- Nicotine Patch, 7 Mg/24 Hr
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Schizophrenia
A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia
- Trial name
- NCT00088621
- Testing
- Lurasidone 80mg tablet
- Where
- 21 sites in United States
- Volunteers
- 61 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia
The purpose of this study is to evaluate the effectiveness and safety of Extended Release Osmotic Controlled-Release Oral Delivery System (OROS) Paliperidone compared to placebo in patients with Schizophrenia.
- Trial name
- NCT00396565
- Testing
- ER OROS paliperidone, Olanzapine
- Where
- 56 sites in Japan
- Volunteers
- 394 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
Staccato Loxapine Single Dose PK
The objective of this study was to assess the safety, tolerability and pharmacokinetics of a single inhaled dose of (administered in 1 or 2 puffs) Staccato Loxapine in healthy volunteers.
- Trial name
- NCT00444028
- Testing
- inhaled Loxapine 0.625 mg, inhaled Loxapine 1.25 mg, inhaled Loxapine 2.5 mg
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.